Insmed, Inc. (INSM)
| Market Cap | 3.34B |
| Revenue (ttm) | 164.41M |
| Net Income (ttm) | -294.09M |
| Shares Out | 97.61M |
| EPS (ttm) | -3.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $32.30 |
| Previous Close | $32.25 |
| Change ($) | 0.05 |
| Change (%) | 0.16% |
| Day's Open | 31.95 |
| Day's Range | 31.39 - 32.47 |
| Day's Volume | 473,827 |
| 52-Week Range | 18.58 - 45.44 |
BRIDGEWATER, N.J., April 7, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., March 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed Incorporated (NASDAQ: INSM) has announced topline results from the Phase 1 study evaluating treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The company plans to present comp...
BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRIDGEWATER, N.J., Feb. 16, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Feb. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
BRIDGEWATER, N.J., Dec. 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.
BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Nov. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call Transcript
Insmed (INSM) delivered earnings and revenue surprises of -6.78% and -6.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BRIDGEWATER, N.J., Oct. 29, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRIDGEWATER, N.J., Oct. 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
BRIDGEWATER, N.J., Sept. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
On Friday, Insmed (INSM) hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 83, up from 79 the day before.
Insmed Incorporated (INSM) CEO William Lewis on Q2 2020 Results - Earnings Call Transcript
Insmed (INSM) delivered earnings and revenue surprises of -10.34% and 16.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
BRIDGEWATER, N.J., July 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
BRIDGEWATER, N.J., June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...
BRIDGEWATER, N.J., June 8, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...
Insmed Incorporated (INSM) CEO Will Lewis on Q1 2020 Results - Earnings Call Transcript
Insmed (INSM) delivered earnings and revenue surprises of -10.45% and 9.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Insmed (NASDAQ:INSM) were unchanged at $21.05 after the company reported Q1 results.
Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insmed, Incorporated (INSM) CEO Will Lewis on Q4 2019 Results - Earnings Call Transcript
Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares jump in response to a pair of analyst upgrades.
Shares soar after Insmed reports upbeat clinical news.
Insmed Inc. (NASDAQ: INSM) is one of the few biotechs not tied to the coronavirus that is making a big move to start out the week.
Insmed stock rocketed Monday after the biotech company said its non-cystic fibrosis bronchiectasis treatment showed promise in a Phase 2 study. Patients experienced fewer exacerbations.
Shares of Insmed Inc. INSM, -1.11% rocketed 51% toward a nine-month high in premarket trading Monday, after the biopharmaceutical company said a phase 2 trial of its treatment of non-cystic fibrosis bro...
Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Insmed, Inc. (INSM) CEO Will Lewis on Q3 2019 Results - Earnings Call Transcript
Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a tr... [Read more...]
| Industry Biotechnology | IPO Date Jun 1, 2000 |
| CEO William Lewis | Employees 521 |
| Stock Exchange NASDAQ | Ticker Symbol INSM |
Financial Performance
In 2020, Insmed's revenue was $164.41 million, an increase of 20.48% compared to the previous year's $136.47 million. Losses were -$294.09 million, 15.6% more than in 2019.
Analyst Forecasts
According to 9 analysts, the average rating for Insmed stock is "Strong Buy." The 12-month stock price forecast is 53.56, which is an increase of 65.82% from the latest price.